A. Power

发表

Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy.

H. Atkins, D. Roy, J. Bell, 2015, Journal of controlled release : official journal of the Controlled Release Society.

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

H. Atkins, J. Hiscott, J. Bell, 2003, Cancer cell.

Vesicular stomatitis virus: re-inventing the bullet.

J. Bell, B. Lichty, D. Stojdl, 2004, Trends in molecular medicine.

Synthesis and Characterization of a Biotinylated Multivalent Targeted Contrast Agent.

N. Logothetis, M. Maier, G. Angelovski, 2015, ChemPlusChem.

Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer.

J. Bell, A. Power, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy

J. Bell, A. Power, 2008, Gene Therapy.

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

H. Atkins, J. Bell, Kelley A. Parato, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Cell carriers for systemic delivery of oncolytic viruses

A. Power, 2010 .

Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSVΔM51) on Multifocal and Invasive Gliomas

T. Alain, R. Johnston, J. Bell, 2006 .

Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.

S. Russell, J. Bell, S. K. Carlson, 2007, Blood.

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

T. Alain, R. Johnston, J. Bell, 2006, Journal of the National Cancer Institute.